Table II.
Univariable and multivariable analyses.
| PFS | OS | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariable | Multivariable | Univariable | Multivariable | |||||
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age (years) | ||||||||
| ≤50 | Referent | 0.619 | Referent | 0.1984 | Referent | 0.567 | Referent | 0.9678 |
| >50 | 1.265 (0.498–3.324) | 0.454 (0.141–1.540) | 1.322 (0.502–3.542) | 1.022 (0.348–3.225) | ||||
| Preoperative CA-125 value (U/ml) | ||||||||
| ≤35 | Referent | 0.0052 | – | Referent | 0.0078 | – | ||
| >35 | 8.163 (1.671–147.183) | 7.646 (1.553–138.162) | ||||||
| Ascites volume (ml) | ||||||||
| ≤100 | Referent | 0.0054 | – | Referent | 0.0079 | – | ||
| >100 | 4.558 (1.570–14.866) | 4.501 (1.491–14.981) | ||||||
| FIGO stage | ||||||||
| I–II | Referent | 0.0031 | Referent | 0.0014 | Referent | 0.0106 | Referent | 0.0111 |
| III–IV | 4.564 (1.720–11.731) | 5.696 (2.018–116.282) | 3.970 (1.405–10.280) | 3.978 (1.397–10.865) | ||||
| Surgery | ||||||||
| Standard surgery+full staging | Referent | 0.3686 | – | Referent | 0.457 | – | ||
| Other surgery | 1.589 (0.552–4.097) | 1.505 (0.477–4.076) | ||||||
| Residual tumor | ||||||||
| No | Referent | 0.0229 | – | Referent | 0.0302 | – | ||
| Yes | 3.888 (1.233–10.472) | 4.227 (1.170–12.241) | ||||||
| Chemotherapy | ||||||||
| Platinum-based | Referent | 0.830 | – | Referent | 0.9344 | – | ||
| Taxane plus platinum | 0.890 (0.329–2.808) | 0.956 (0.344–3.060) | ||||||
| KIF20A expression | ||||||||
| Low | Referent | 0.0374 | Referent | 0.0136 | Referent | 0.0512 | Referent | 0.0897 |
| High | 2.979 (1.061–10.562) | 5.488 (1.410–24.772) | 2.833 (0.995–10.117) | 2.835 (0.854–11.035) | ||||
KIF20A, Kinesin family member 20A; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; 95% CI, 95% confidence interval; CA-125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics.